Aptalis Pharmaceutical Technologies Release: Allegra Dry Syrup 5% Launches In Japan

Bridgewater, NJ–February 19, 2015–Sanofi K.K. has announced that Allegra® Dry Syrup 5% has launched in Japan. This new formulation of fexofenadine HCI was the result of a codevelopment partnership between Sanofi K.K. and Aptalis Pharmaceutical Technologies.

Allegra® Dry Syrup 5% is indicated for the treatment of allergic rhinitis, urticaria, and pruritus associated with dermal disorders such as eczema/dermatitis, pruritus cutaneous, and atopic dermatitis.

By employing the use of Microcaps® Taste Masking Technology, Aptalis Pharmaceutical Technologies successfully masked the taste of the bitter API—delivering a formulation with a pleasant taste in a dosage form that features white granules that can be sprinkled on easy-toswallow foods to further improve convenience of administration. This formulation can be used with or without the need for water or mixed into a liquid suspension. Microcaps® is a proprietary technology that provides complete and uniform encapsulation of drug particles in a polymeric membrane of adjustable thickness. It can be applied to crystals, drug-layered beads, or granules and can be combined with pore-former technology to ensure rapid release in the stomach while maintaining effective taste masking to ensure palatability.

Allegra® Dry Syrup 5% is an appropriate alternative to the tablet formulation for pediatric patients and adult patients who have difficulty swallowing.

For full access, please click here.

Help employers find you! Check out all the jobs and post your resume.

Back to news